ClinicalTrials.gg
CompletedNCT02583399Updated Nov 20, 2020Results posted

Safety and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients

A Phase 4 interventional study of Ibuprofen in Pain and Fever, sponsored by Cumberland Pharmaceuticals. Completed at 4 sites in United States. Open to participants aged Up to 6 Months. Per ClinicalTrials.gov, last updated 2020-11-20.

Sponsored by Cumberland Pharmaceuticals · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
Up to 6 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.

Enrollment
72nd of 86
30 · median 100
Started
2017
with 7 others
Phase 4
30 of 86
3 open now
Registered
46th of 86
by date
Lead sponsor
6 of 86
Cumberland Pharmaceuticals

Among the 86 studies testing ibuprofen in Pain, this one is the 72nd largest by enrollment, is one of 8 that started in 2017, is one of 30 in phase 4, and was the 46th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: Up to 6 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing ibuprofen in Pain, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the pharmacokinetic profile of a single dose of intravenous ibuprofen administered over approximately ten (10) minutes.

Read the detailed description

The primary objective of this study is to evaluate the pharmacokinetic profile of a single dose of intravenous ibuprofen administered over approximately ten (10) minutes.

03

Conditions studied

  • Pain
  • Fever

Browse trials for

Keywords

  • Pediatric (Birth to less than 6 months of age)
  • Pain
  • Fever
04

Who can participate

Ages eligible
Up to 6 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be a hospitalized male or female subject between birth (> 37 weeks gestational age) and \< six (6) months of age.
  • Have a clinical indication of pain or fever.
  • Have written provided by legal parent, guardian, or authorized agent prior to participation in the study or performance of any study-only related procedures.

Exclusion criteria

Exclusion Criteria:

  • Have inadequate intravenous access.
  • Have an uncorrected ductus dependent congenital heart disease.
  • Have any history of allergy or to non-steroidal anti-inflammatory drug or aspirin.
  • Have a current history of uncorrected hypovolemia or acute renal disease.
  • Have a current history of acute liver disease.
  • Have received NSAID, acetaminophen, or aspirin drug therapy within four hours prior to dosing. Have received another drug within the past 30 days.
  • Be otherwise unsuitable for the study, in the opinion of the Investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Ibuprofen

    Ibuprofen, 10 mg/kg

    Drug: Ibuprofen

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) 0-4 Hours of a Single Dose of Intravenous Ibuprofen (IVIb) Administered Over 5-7 Minutes.

    This outcome measurement was to the determine the area under the plot of plasma concentrations of drug against time after drug administration. Pharmacokinetic samples were collected immediately following the first dose, the utilizing sparse sampling techniques, samples were collected at 30 minutes, 1 hour, 2 hours and 4 hours.

    Time frame: 4 hours

  2. Maximum Observed Plasma Concentration (Cmax) of a Single Dose of Intravenous Ibuprofen (IVIb) Administered Over 5-7 Minutes.

    This outcome measurement was to measure the maximal or peak measured serum concentration (Cmax) of a single dose of intravenous ibuprofen (IVIb) after its administration. Pharmacokinetic samples were collected immediately following the first dose, the utilizing sparse sampling techniques, samples were collected at 30 minutes, 1 hour, 2 hours and 4 hours.

    Time frame: 4 hours

  3. Elimination Half Life (T 1/2) of a Single Dose of Intravenous Ibuprofen (IVIb) Administered Over 5-7 Minutes.

    This outcome measurement was to determine the half-life or the period of time required for the concentration or amount of drug in the body to be reduced to exactly one-half of a given concentration or amount. Pharmacokinetic samples were collected immediately following the first dose, the utilizing sparse sampling techniques, samples were collected at 30 minutes, 1 hour, 2 hours and 4 hours.

    Time frame: 4 hours

  4. Time to Maximum Concentration (Tmax) of a Single Dose of Intravenous Ibuprofen (IVIb) Administered Over 5-7 Minutes.

    This outcome measurement was to determine the time to maximum concentration (Tmax) of a single dose of intravenous ibuprofen (IVIb) after its administration. Pharmacokinetic samples were collected immediately following the first dose, the utilizing sparse sampling techniques, samples were collected at 30 minutes, 1 hour, 2 hours and 4 hours.

    Time frame: 4 hours

07

Results

Posted Nov 20, 2020

Participant flow

Enrollment occurred between 08-Aug2017 and 21-Feb2019. Subject were recruited were hospitalized pediatric subjects, aged birth (greater than 37 weeks gestational age) to less than six months of age, with a clinical indication of pain and fever.

Participant flow — Overall Study
MilestoneIbuprofen
Started30
Completed24
Not completed6
Withdrew: Able to be discharged3
Withdrew: Wanted to use a restricted medication3

Outcome measures

PrimaryArea Under the Curve (AUC) 0-4 Hours of a Single Dose of Intravenous Ibuprofen (IVIb) Administered Over 5-7 Minutes.

This outcome measurement was to the determine the area under the plot of plasma concentrations of drug against time after drug administration. Pharmacokinetic samples were collected immediately following the first dose, the utilizing sparse sampling techniques, samples were collected at 30 minutes, 1 hour, 2 hours and 4 hours.

Time frame:
4 hours
Reported as:
Mean · mcg*hr/mL
Area Under the Curve (AUC) 0-4 Hours of a Single Dose of Intravenous Ibuprofen (IVIb) Administered Over 5-7 Minutes.
mcg*hr/mLIbuprofen
Area Under the Curve (AUC) 0-4 Hours of a Single Dose of Intravenous Ibuprofen (IVIb) Administered Over 5-7 Minutes.75.74 ± 4.09
PrimaryMaximum Observed Plasma Concentration (Cmax) of a Single Dose of Intravenous Ibuprofen (IVIb) Administered Over 5-7 Minutes.

This outcome measurement was to measure the maximal or peak measured serum concentration (Cmax) of a single dose of intravenous ibuprofen (IVIb) after its administration. Pharmacokinetic samples were collected immediately following the first dose, the utilizing sparse sampling techniques, samples were collected at 30 minutes, 1 hour, 2 hours and 4 hours.

Time frame:
4 hours
Reported as:
Mean · microgram/milliliter
Maximum Observed Plasma Concentration (Cmax) of a Single Dose of Intravenous Ibuprofen (IVIb) Administered Over 5-7 Minutes.
microgram/milliliterIbuprofen
Maximum Observed Plasma Concentration (Cmax) of a Single Dose of Intravenous Ibuprofen (IVIb) Administered Over 5-7 Minutes.56.28 ± 2.77
PrimaryElimination Half Life (T 1/2) of a Single Dose of Intravenous Ibuprofen (IVIb) Administered Over 5-7 Minutes.

This outcome measurement was to determine the half-life or the period of time required for the concentration or amount of drug in the body to be reduced to exactly one-half of a given concentration or amount. Pharmacokinetic samples were collected immediately following the first dose, the utilizing sparse sampling techniques, samples were collected at 30 minutes, 1 hour, 2 hours and 4 hours.

Time frame:
4 hours
Reported as:
Number · hours
Elimination Half Life (T 1/2) of a Single Dose of Intravenous Ibuprofen (IVIb) Administered Over 5-7 Minutes.
hoursIbuprofen
Elimination Half Life (T 1/2) of a Single Dose of Intravenous Ibuprofen (IVIb) Administered Over 5-7 Minutes.1.30
PrimaryTime to Maximum Concentration (Tmax) of a Single Dose of Intravenous Ibuprofen (IVIb) Administered Over 5-7 Minutes.

This outcome measurement was to determine the time to maximum concentration (Tmax) of a single dose of intravenous ibuprofen (IVIb) after its administration. Pharmacokinetic samples were collected immediately following the first dose, the utilizing sparse sampling techniques, samples were collected at 30 minutes, 1 hour, 2 hours and 4 hours.

Time frame:
4 hours
Reported as:
Number · minutes
Time to Maximum Concentration (Tmax) of a Single Dose of Intravenous Ibuprofen (IVIb) Administered Over 5-7 Minutes.
minutesIbuprofen
Time to Maximum Concentration (Tmax) of a Single Dose of Intravenous Ibuprofen (IVIb) Administered Over 5-7 Minutes.10

Adverse events

Collected over Adverse events were assessed during the treatment period beginning with the start of the study drug administration through study hour 72 or until discharge, whichever occurs first.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibuprofen8/24 (33.3%)1/24 (4.2%)7/24 (29.2%)
Most frequent serious events
Most frequent serious events
EventIbuprofen
Pericardial effusionCardiac disorders1/24
ChylothoraxCardiac disorders1/24
Most frequent other events
Most frequent other events
EventIbuprofen
ConstipationGastrointestinal disorders2/24
Eye dischargeEye disorders1/24
Post-procedural feverInjury, poisoning and procedural complications1/24
White blood cells increasedInvestigations1/24
HypokalemiaMetabolism and nutrition disorders1/24
AtelectasisRespiratory, thoracic and mediastinal disorders1/24
ChylothoraxRespiratory, thoracic and mediastinal disorders1/24
Pleural effusionRespiratory, thoracic and mediastinal disorders1/24
Peripherial artery thrombosisVascular disorders1/24

Baseline characteristics

Age, Continuous
Age, Continuous(days)Ibuprofen
Mean127.7 ± 33.77
Sex: Female, Male
Sex: Female, Male(Participants)Ibuprofen
Female9
Male15
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ibuprofen
Black or African American3
White17
Other4
Hispanic/Latino5
Non-Hispanic/Non-Latino19
Weight
Weight(kilograms)Ibuprofen
Mean6 ± 1.45
08

Study locations

4 sites
  • Kosair Charaties Pediatric Research Unit
    Louisville, Kentucky 40202, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Children's Medical Center Dallas
    Dallas, Texas 75235, United States
  • Baylor College of Medicine/Texas Children's Hospital
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Jul 2019, 22 months.

Results were first posted in Nov 2020, 1 year 4 months after primary completion.

Of 295 phase 4 interventional studies under Pain, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 22 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2015
First posted
Oct 22, 2015
StartActual
Aug 8, 2017
Primary completionActual
Jul 2, 2019
CompletionActual
Jul 2, 2019
Results first posted
Nov 20, 2020
Last update
Nov 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02583399
Responsible party
Sponsor
First posted
Oct 22, 2015
Start date
Aug 8, 2017
Primary completion
Jul 2, 2019
Completion
Jul 2, 2019
Results posted
Nov 20, 2020
Last update
Nov 20, 2020

Study contacts

Todd Rice, MD
study chair · Vanderbilt University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion